GCCHX | SMCFX | GCCHX / SMCFX | |
Total Expense Ratio | 0.77 | 0.76 | 101% |
Annual Report Gross Expense Ratio | 0.82 | 0.76 | 108% |
Fund Existence | 8 years | 17 years | - |
Gain YTD | 2.022 | 0.490 | 412% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 250 | 400,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 480M | 74.5B | 1% |
Annual Yield % from dividends | 0.74 | 0.90 | 83% |
Returns for 1 year | -19.85 | 0.68 | -2,910% |
Returns for 3 years | -32.11 | 18.87 | -170% |
Returns for 5 years | -1.37 | 24.26 | -6% |
Returns for 10 years | N/A | 38.65 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FBDIX | 112.13 | N/A | N/A |
Franklin Biotechnology Discovery A | |||
BRIFX | 16.37 | N/A | N/A |
Baron Real Estate Income Retail | |||
HROAX | 12.18 | -0.16 | -1.30% |
M3Sixty Income and Opportunity A | |||
DFUEX | 28.31 | -0.56 | -1.94% |
DFA US Social Core Equity 2 Portfolio | |||
JGAQX | 36.32 | -0.83 | -2.23% |
JPMorgan Value Advantage R2 |